Bayer AG
BAYN: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€75.00 | Wjczsr | Trgf |
Bayer’s Core Business Lines in Healthcare and Crop Sciences Look Well Positioned Over the Long Term
Business Strategy and Outlook
Largely on the basis of the strong competitive advantages of the healthcare group and to a lesser extent the crop science business, we believe Bayer has created a wide economic moat. Also, the past divestiture of no-moat material science group Covestro leaves the company in a stronger competitive position.